Deep Track Capital Reports 8.46% Stake in Tarsus Pharmaceuticals, Inc.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Tarsus Pharmaceuticals, Inc. (TARS). The filing indicates that as of the event date on March 31, 2026, the reporting persons collectively held 3,600,000 shares of common stock, representing an 8.46% ownership stake in the company. This reflects a significant increase from their previously reported position of zero shares. The shares are held with shared voting and dispositive power. David Kroin, as the Managing Member of the General Partner of the Investment Adviser, may be considered a control person for these entities. The filing was made under Rule 13d-1(c), certifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The calculation of the ownership percentage is based on 42,557,492 shares of common stock outstanding as of February 17, 2026.